ERCC2 Genotype

Some people smoke for decades and never develop cancer, while others exposed to the same toxins do. Part of that difference lives in the genes that fix everyday damage to your DNA, and this one is among the most studied of them.

This test reads which inherited version of ERCC2 (also known as XPD) you carry. It is a research-grade marker rather than a diagnosis, but it can offer an early, exploratory window into how your body handles DNA-damaging exposures and how the science of DNA repair may relate to your long-term risk.

What This Gene Actually Does

ERCC2 carries the instructions for a protein called XPD, part of a larger repair machine that unwinds the DNA double helix so your cells can cut out and replace damaged sections. This clean-up crew, called nucleotide excision repair, is how your cells undo damage from ultraviolet light, tobacco smoke, and other environmental chemicals.

The most commonly reported variations sit at specific spots in the gene, with technical names like rs1799793, rs13181, and rs238406. Because this is a fixed germline genotype, the version you inherited at birth is the version you keep for life, in every cell of your body.

Why There Is No Single Risk Genotype

It is tempting to expect one version of this gene to be simply good or bad. The evidence does not work that way. The same variant can look protective in one population and risky in another, or matter only when combined with a specific exposure like heavy smoking.

This is not a good-number-bad-number marker. It is better understood as a repair-pathway indicator whose meaning shifts with your ancestry and your environment. One careful review concluded there is no convincing evidence that the two most common variations meaningfully impair DNA repair on their own, though other laboratory studies have measured real effects on repair capacity. That debate is still open, and it helps explain why study results so often disagree.

Smoking-Related Cancers

The clearest human signals appear when a variant meets a strong exposure. In a study of pancreatic cancer, heavy smokers carrying at least one minor version at the rs1799793 spot had nearly three times the risk compared with non-carriers (odds ratio 2.78, 95% CI 1.28 to 6.04). Outside of that smoking subgroup, no broad signal was detected.

A similar pattern shows up in esophageal squamous cell cancer in Chinese populations, where the rs238406 variant raised risk and interacted with smoking history. The takeaway is that your genotype may matter most in combination with what you expose your cells to, not in isolation.

Breast Cancer

In a German study of more than 1,400 women, a particular combination of ERCC2 versions at the codon 312 and codon 751 positions was associated with higher breast cancer risk, and one specific inherited pattern stood out as the strongest risk combination. This is a susceptibility finding from a single ancestry group, and larger pooled analyses have not confirmed an overall breast cancer link, so it should be read as one piece of a larger picture rather than a verdict.

Stomach Cancer

A pooled analysis of multiple studies found that certain ERCC2 genotypes were linked to higher gastric cancer risk in Asian populations, with much weaker and less consistent signals in people of European descent, though at least one European study did find a link for one stomach cancer subtype. This ancestry split is one of the most consistent themes across the whole body of research on this gene, and it is why the same result can mean different things for different people.

Arsenic Exposure and Skin Changes

In arsenic-exposed communities in India, people carrying the codon 751 Lys/Lys version were far more likely to develop premalignant thickened skin patches, with almost five times the odds (odds ratio 4.77, 95% CI 2.75 to 8.23), along with more chromosome damage. This finding is not consistent across studies, though: a larger study in Bangladesh found no independent link between this genotype and arsenic-related skin lesions. If you have known heavy-metal exposure, that context changes how relevant this marker becomes.

Male Fertility

A genotyping study in Indian men linked the AA genotype at the codon 751 spot to a higher risk of male infertility, including severely low sperm production. The signal was population-specific: when the same researchers pooled data across different Asian populations the overall link disappeared, and an earlier Chinese study pointed to the opposite allele as the risky one. This does not translate automatically to every ancestry.

Severe Inherited Repair Disorders

It is worth separating the common variations this test reports from rare, disabling mutations in the same gene. When both copies of ERCC2 carry severe damaging mutations, the result is a serious repair-deficiency condition such as xeroderma pigmentosum or trichothiodystrophy, marked by extreme sun sensitivity and, in some cases, neurological problems. These are different in kind from the everyday polymorphisms most people carry, and carrying a common variant does not put you anywhere near this category.

Chemotherapy Response: Inherited Versus Tumor Findings

Some of the most striking ERCC2 headlines come from bladder cancer, where mutations found inside the tumor itself predict strong responses to platinum chemotherapy. Those are somatic changes that appear in cancer cells, not the inherited genotype this test measures, and the two should never be treated as the same thing.

For inherited variations, the treatment evidence is more modest and population-specific. In people of European descent treated with oxaliplatin for stomach or colon cancer, the rs13181 G version was linked to roughly 40% worse survival and progression outcomes, while several lung cancer analyses found no reliable effect at all. This is emerging, uneven evidence, not an established rule.

A One-Time Result You Use for Years

Because this is a fixed germline genotype, you only need to test it once. The result will read the same next year and every year after, so there is no trend to track and no reason to repeat it unless a laboratory needs to confirm an unexpected call using a second method.

The value of this test comes not from retesting but from integrating the result into decisions over time. If you carry a variant tied to smoking-related or exposure-related cancer risk, the practical move is to keep routine cancer screening on schedule and reduce your known exposures for the rest of your life.

What to Do With an Unexpected Result

A single genotype should never drive a health decision on its own. If your result flags a variant, the useful next step is to look at the whole pattern: your family history, your ancestry, your exposure history like tobacco or arsenic, and any personal cancer history. A variant plus heavy smoking is a very different situation from the same variant in a never-smoker with no family history.

If a variant lines up with a strong family history of a specific cancer, that is the moment to bring in a genetics professional or the relevant specialist, who can decide whether earlier or more frequent screening makes sense. Think of this genotype as one input into a conversation about your overall risk, not a standalone answer.

When Results Can Be Misleading

A few specific issues can make a genetic result misleading rather than a lab error you can see:

• Panel coverage: the assay only detects the specific variants it is designed to read, so a result showing no common variant does not rule out other rare changes in the same gene.
• Ancestry effects: many of these variants are common in one population and rare in another, and their disease meaning was often established in only one ancestry group, so your background shapes how to read the result.
• Uncertain variants: an unexpected change may be reported with no clear clinical meaning yet, which is a genuine unknown rather than a confirmed risk.
• Germline versus tumor: this test reads the inherited DNA you were born with, not mutations inside a tumor, and confusing the two leads to the wrong conclusions about chemotherapy or cancer risk.